Repligen Corporation
General ticker "RGEN" information:
- Sector: Health Care
- Industry: Medical - Instruments & Supplies
- Capitalization: $7.7B (TTM average)
Repligen Corporation follows the US Stock Market performance with the rate: 47.2%.
Estimated limits based on current volatility of 2.4%: low 128.08$, high 134.35$
Factors to consider:
- Total employees count: 1778 (-0.3%) as of 2024
- Top business risk factors: Market competition, Operational and conduct risks, Climate change and natural disasters, Liquidity and credit risks, Integration challenges
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [127.01$, 193.15$]
- 2026-12-31 to 2027-12-31 estimated range: [129.42$, 196.98$]
Financial Metrics affecting the RGEN estimates:
- Negative: with PPE of 95.7 at the end of fiscal year the price was high
- Positive: 7.68 < Operating profit margin, % of 8.07
- Positive: Shareholder equity ratio, % of 71.40 > 64.25
- Positive: Interest expense per share per price, % of 0.25 <= 0.73
- Positive: Inventory ratio change, % of 0.46 <= 0.80
- Positive: -3.36 < Return on assets ratio (scaled to [-100,100]) of 1.63
- Negative: Industry operating profit margin (median), % of -1.25 <= 3.02
- Negative: Industry inventory ratio change (median), % of 0.78 > 0.31
Short-term RGEN quotes
Long-term RGEN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $632.36MM | $634.44MM | $738.26MM |
| Operating Expenses | $584.66MM | $669.55MM | $678.68MM |
| Operating Income | $47.70MM | $-35.11MM | $59.58MM |
| Non-Operating Income | $9.00MM | $8.08MM | $2.81MM |
| Interest Expense | $2.50MM | $20.73MM | $23.17MM |
| R&D Expense | $42.72MM | $43.20MM | $54.18MM |
| Income(Loss) | $56.71MM | $-27.04MM | $62.38MM |
| Taxes | $21.11MM | $-1.52MM | $13.49MM |
| Profit(Loss)* | $29.61MM | $-25.51MM | $48.89MM |
| Stockholders Equity | $1,964.85MM | $1,972.72MM | $2,106.13MM |
| Inventory | $202.32MM | $142.96MM | $170.46MM |
| Assets | $2,831.18MM | $2,829.67MM | $2,949.70MM |
| Operating Cash Flow | $113.92MM | $175.39MM | $117.42MM |
| Capital expenditure | $38.99MM | $32.91MM | $23.52MM |
| Investing Cash Flow | $-123.28MM | $-86.38MM | $-298.47MM |
| Financing Cash Flow | $248.96MM | $-82.90MM | $-15.21MM |
| Earnings Per Share** | $0.53 | $-0.46 | $0.87 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.